Brief: Akoustis Technologies Says Effective As Of May 24, 2022, Co Suspended Sales Under Its Previously-Announced 'At Market' Equity Offering Program
26/05/2022 12:14
May 26 (Reuters) - Akoustis Technologies Inc AKTS.O :
* AKOUSTIS TECHNOLOGIES - EFFECTIVE AS OF MAY 24, 2022, CO
SUSPENDED SALES UNDER ITS PREVIOUSLY-ANNOUNCED "AT MARKET"
EQUITY OFFERING PROGRAM
Source: [ID: https://bit.ly/3MU2bl8]
Further company coverage: AKTS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aktis Oncology
See all newsAktis Oncology Q2 net loss widens on higher R&D, administrative costs
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI
Aktis Oncology Q1 net loss widens on increased IPO-related expenses
Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer (updated)
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut